A third vaccine dose equalises the levels of effectiveness and immunogenicity of heterologous or homologous COVID-19 vaccine regimens, Lyon, France, December 2021 to March 2022

BACKGROUND: To cope with the persistence of the COVID-19 epidemic and the decrease in antibody levels following vaccination, a third dose of vaccine has been recommended in the general population. However, several vaccine regimens had been used initially for the primary vaccination course, and the h...

Descripción completa

Detalles Bibliográficos
Autores principales: Guibert, Nicolas, Trepat, Kylian, Pozzetto, Bruno, Josset, Laurence, Fassier, Jean-Baptiste, Allatif, Omran, Saker, Kahina, Brengel-Pesce, Karen, Walzer, Thierry, Vanhems, Philippe, Trouillet-Assant, Sophie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103547/
https://www.ncbi.nlm.nih.gov/pubmed/37052679
http://dx.doi.org/10.2807/1560-7917.ES.2023.28.15.2200746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103547/
https://www.ncbi.nlm.nih.gov/pubmed/37052679
http://dx.doi.org/10.2807/1560-7917.ES.2023.28.15.2200746

Ejemplares similares